More companies going with prefilled syringes ahead of flu season

Prefilled syringes continue to gain popularity for drug delivery with more U.S. biopharmaceutical companies moving away from vials in advance of the upcoming flu season, reports In-PharmaTechnologist. Prefilled syringes are secure, easy to use, minimize the chance for dosage error and increase patient compliance.

In-PharmaTechnologist reports that even though Europe has adopted prefilled syringes in greater numbers, the shift has picked up in the past few months. "There's been a migration to more prefill applications for the upcoming flu season [in the US]," Bill Kozy, executive vice president at medical supply company BD, said in a conference call, adding that the company has done its part to make the shift happen with its "vial to prefill strategy," In-PharmaTechnologist reports.

BD's clients in the United States have added $9 million to third-quarter sales, according to the report, with U.S. sales getting a boost from "a big pharmaceutical client shifting its sourcing from Europe to North America."

- read more in In-PharmaTechnologist

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Suggested Articles

Iowa State University is working on a room-temp-stable nasal spray vaccine for COVID-19, and it recently tapped device maker Zeteo for support.

ApiJect systems snared a $590 million from the U.S. government to build a multi-facility campus to crank out more than 3 billion injectors per year.

A team at the University of New South Wales Sydney developed a light-activated liposome that could deliver CRISPR treatments with fewer side effects.